Ardelyx Reports First Quarter 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 05/03/23
Ardelyx Announces Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with IBS-C, to be Presented at the 2023 Digestive Disease Week ConferenceGlobeNewsWire • 05/01/23
Ardelyx to Report First Quarter 2023 Financial Results and Provide Business Update on May 3, 2023GlobeNewsWire • 04/26/23
Ardelyx Presents Positive Data Further Supporting Efficacy and Safety of XPHOZAH® (tenapanor) at National Kidney Foundation 2023 Spring Clinical MeetingsGlobeNewsWire • 04/12/23
Ardelyx Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdateGlobeNewsWire • 03/02/23